SCHEMBL1945852

SCHEMBL1945852

COc1ccc(CNc2nn3cc(-c4cccnc4)nc3s2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 5/20 0.55
LMNA P02545 1/20 0.55
HTT P42858 1/20 0.55
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
FYN P06241 5/20 0.52
ALDH1A1 P00352 4/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
KLKB1 P03952 4/20 0.52
KLK1 P06870 1/20 0.52
MAPT P10636 5/20 0.52
KMT2A Q03164 4/20 0.52
MEN1 O00255 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
DYRK1A Q13627 1/20 0.51
CLK4 Q9HAZ1 1/20 0.51
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
GAA P10253 1/20 0.51
F2RL3 Q96RI0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15603219 0.89 F2RL3 (0.58) LMNAFYNMAPTSMN1; SMN2KDM4E
SCHEMBL1946899 0.88 F2RL3 (0.57) LMNAHTTFYNALDH1A1MAPT
SCHEMBL1945033 0.87 FYN (0.54) F2FYNALDH1A1KLKB1MAPT
SCHEMBL1944440 0.87 FYN (0.62) F2LMNAMAPK1FYNALDH1A1
SCHEMBL1945259 0.87 FYN (0.67) LMNAFYNMAPTF2RL3
SCHEMBL1945749 0.87 MAPT (0.52) F2LMNAFYNALDH1A1KLKB1
SCHEMBL1943569 0.86 FYN (0.48) F2LMNATSHRMAPK1FYN
SCHEMBL1945239 0.85 FYN (0.55) LMNATSHRMAPK1FYNALDH1A1
SCHEMBL1946444 0.85 FYN (0.53) LMNAFYNMAPTF2RL3
SCHEMBL1947352 0.84 F2RL3 (0.52) FYNMAPTKMT2AMEN1F2RL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R F2 3002/4885LMNA 3477/4885HTT 4800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.